RxDoctor Payments Data

Lauren Treharn, APRN

Psychiatric/Mental Health · North Lima, OHNPI 1487112223

Payments from drug & device makers

$1,003in general payments, 2019–2025

Across 34 payments — averaging $29.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$280
  • Otsuka America Pharmaceutical, Inc.$229
  • Sanofi$135
  • Axsome Therapeutics, Inc.$113
  • Alkermes, Inc.$94
  • Johnson & Johnson$90
  • plus $62 from 3 others

What the payments were for

  • Food & beverage$95695%
  • Education$475%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,003 in reported general payments places this provider in the 60th percentile of 1,808 psychiatric/mental health providers in Ohio.

See all psychiatric/mental health providers in Ohio

Medicare billing

Part B allowed, 2024
$12,095
Medicare patients
22
Services billed
154

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole84$128,416
VyvanseLisdexamfetamine Dimesylate39$14,534
Lurasidone Hcl20$7,406
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine210$6,680
BelsomraSuvorexant12$5,412
Aripiprazole101$4,179
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine55$3,543
Vilazodone Hcl25$2,536
Quetiapine Fumarate270$2,460
Paliperidone ErPaliperidone22$1,951
Duloxetine Hcl126$1,910
Bupropion XlBupropion Hcl134$1,415
Methylphenidate Hcl37$1,312
Venlafaxine Hcl ErVenlafaxine Hcl158$1,222
Alprazolam217$1,197

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$229$128,41684 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,808 psychiatric/mental health providers in Ohio.

Other psychiatric/mental health in North Lima

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →